Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
NEW YORK, Feb. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased Cardiovascular Systems, Inc. (NASDAQ:CSII) securities between September 12, 2011 and January 21, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/cardiovascular-systems. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Cardiovascular Systems distributed illegal kickbacks to health care providers; (2) Cardiovascular Systems engaged in the off-label promotion of its medical devices; and (3) Cardiovascular Systems violated FDA laws and regulations in connection with its medical devices. As a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Cardiovascular Systems you have until April 12, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/cardiovascular-systems.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
